Context Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $9 price target Context is a pioneer in developing T-cell engagers and its lead program, CTIM-76, is about to enter the clinic, the analyst tells investors in a research note. The firm says CTIM-76 is targeting a novel and highly specific tumor marker, Claudin 6. This protein is widely expressed in solid tumors, such as gynecologic and testicular cancers, but is largely absent in healthy adult tissues, making it an attractive therapeutic target, contends D. Boral.